ERBB2 and gastric cancer: The combination of chemotherapy and treatment with trastuzumab, which is an antibody against human epidermal growth factor receptor 2 (HER2), is thus far the only proven targeted therapy that is indicated for patients with HER2-positive gastric cancer [3].